Volume : 09, Issue : 07, July – 2022



Authors :

Ahmed Salman Saeed Alsharef, Maryam salman Alsharif

Abstract :

Study aim: This systematic review aims to quantitatively assess vascular and lymphovascular invasion as prognostic factors for pancreatic adenocarcinoma. Methods: We carried out this systematic review meta-analysis in accordance with the PRISMA guidelines. We searched PubMed and EMBASE using EBSCO. We used Rayyan (Intelligent Systematic Reviews) website for duplication removal and study screening, and we used Review Manager 5.4 software to conduct a random-effect model meta-analysis pooling hazard ratios extracted from the included studies. Results: The study included 17 studies. The total number of participants from all studies was 5256 patients diagnosed with pancreatic cancer. The random-effects model analysis found that the pooled HR for vascular invasion is 1.37 (95% CI: 1.14, 1.6), where the test for the overall effect is significant (p<0.001). We found that the pooled HR for lymphovascular invasion is 1.44 (95% CI: 1.06, 1.83), where the test for the overall effect is significant (p<0.001). Analyses show significant inter-study heterogeneity for both investigations (I2 > 50%). Conclusion: Our meta-analysis showed that both vascular invasion and lymphovascular invasion have poor prognosis and lower survival outcomes among patients with pancreatic cancer.

Cite This Article:

Please cite this article in press Ahmed Salman Saeed Alsharef et al Survival Outcomes Of Vascular And Lymphovascular Invasion Among Pancreatic Adenocarcinoma Patients: A Systematic Review And Meta-Analysis., Indo Am. J. P. Sci, 2022; 09(7).,

Number of Downloads : 10


1. Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg 2013;257:17-26.
2. Tingstedt B, Weitkamper C, Andersson R. Early onset pancreatic cancer: a controlled trial. Ann Gastroenterol 2011;24:206-12.
3. Zhu Z, Friess H, diMola FF, Zimmermann A, Graber HU, Korc M, et al. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol 1999;17:2419-28.
4. Bartosch-Härlid A, Andersson R. Cachexia in pancreatic cancer – mechanisms and potential intervention. e-SPEN Journal 2009;4:e337-e43.
5. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
6. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, 3rd, Casper ES, et al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2012;10:703-13.
7. Karmazanovsky G, Fedorov V, Kubyshkin V, Kotchatkov A. Pancreatic head cancer: accuracy of CT in determination of resectability. Abdom Imaging 2005;30:488-500.
8. Ansari D, Keussen I, Andersson R. Positron emission tomography in malignancies of the liver, pancreas and biliary tract – indications and potential pitfalls. Scand J Gastroenterol 2013;48:259-65.
9. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378:607-20.
10. Cooper AB, Tzeng CW, Katz MH. Treatment of borderline resectable pancreatic cancer. Curr Treat Options Oncol 2013;14:293-310.
11. Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 2008;9:99-132.
12. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003;27:324-9.
13. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006;10:1199-210; discussion 210-1.
14. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007;246:52-60.
15. Wasif N, Ko CY, Farrell J, Wainberg Z, Hines OJ, Reber H, et al. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol 2010;17:2312-20.
16. Chen JW, Bhandari M, Astill DS, Wilson TG, Kow L, Brooke-Smith M, et al. Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB (Oxford) 2010;12:101-8.
17. Jamieson NB, Foulis AK, Oien KA, Dickson EJ, Imrie CW, Carter R, et al. Peripancreatic fat invasion is an independent predictor of poor outcome following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. J Gastrointest Surg 2011;15:512-24.
18. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curativeintent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-77.
19. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:1019-26.
20. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10.
21. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
22. Erkan M, Michalski CW, Rieder S, Reiser-Erkan C, Abiatari I, Kolb A, et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 2008;6:1155-61.
23. Hiraoka N, Ino Y, Sekine S, Tsuda H, Shimada K, Kosuge T, et al. Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer 2010;103:1057-65.
24. Ansari D, Rosendahl A, Elebro J, Andersson R. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg 2011;98:1041-55.
25. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34.
26. Mourad Ouzzani, Hossam Hammady, Zbys Fedorowicz, and Ahmed Elmagarmid. Rayyan — a web and mobile app for systematic reviews. Systematic Reviews (2016) 5:210, DOI: 10.1186/s13643-016-0384-4.
27. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology (2010) 25, 603–605.
28. Alhasan, S. F., Haugk, B., Ogle, L. F., Beale, G. S., Long, A., Burt, A. D., … & Charnley, R. (2016). Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma. British journal of cancer, 115(7), 797-804.
29. An, W., Ben, Q. W., Chen, H. T., Zheng, J. M., Huang, L., Li, G. X., & Li, Z. S. (2012). Low expression of IGFBP7 is associated with poor outcome of pancreatic ductal adenocarcinoma. Annals of surgical oncology, 19(12), 3971-3978.
30. Ben, Q. W., Wang, J. C., Liu, J., Zhu, Y., Yuan, F., Yao, W. Y., & Yuan, Y. Z. (2010). Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Annals of surgical oncology, 17(8), 2213-2221.
31. Chawla, A., Huang, T. L., Ibrahim, A. M., Hardacre, J. M., Siegel, C., & Ammori, J. B. (2018). Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer. HPB, 20(5), 398-404.
32. Cloyd, J. M., Nogueras-González, G. M., Prakash, L. R., Petzel, M. Q., Parker, N. H., Ngo-Huang, A. T., … & Lee, J. E. (2018). Anthropometric changes in patients with pancreatic cancer undergoing pre-operative therapy and pancreatoduodenectomy. Journal of Gastrointestinal Surgery, 22(4), 703-712.
33. Dal Molin, M., Blackford, A. L., Siddiqui, A., Brant, A., Cho, C., Rezaee, N., … & Wolfgang, C. (2017). Duodenal involvement is an independent prognostic factor for patients with surgically resected pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 24(8), 2379-2386.
34. Drouillard, A., Puleo, F., Bachet, J. B., Ouazzani, S., Calomme, A., Demetter, P., … & Marechal, R. (2016). DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer. British journal of cancer, 115(10), 1245-1252.
35. Hu, S. P., Chen, L., Lin, C. Y., Lin, W. H., Fang, F. Q., & Tu, M. Y. (2020). The prognostic value of pre-operative geriatric nutritional risk index in patients with pancreatic ductal adenocarcinoma. Cancer Management and Research, 12, 385.
36. Marchegiani, G., Andrianello, S., Malleo, G., De Gregorio, L., Scarpa, A., Mino-Kenudson, M., … & Castillo, C. F. D. (2017). Does Size Matter in Pancreatic Cancer?. Annals of surgery, 266(1), 142-148.
37. Morita, K., Oshiro, H., Mito, K., Mieno, M. N., Tamba-Sakaguchi, M., Niki, T., … & Sata, N. (2018). Prognostic significance of the degree of lymphatic vessel invasion in locally advanced, surgically resectable pancreatic head cancer: a single center experience. Medicine, 97(49).
38. Oguro, S., Shimada, K., Ino, Y., Esaki, M., Nara, S., Kishi, Y., … & Hiraoka, N. (2013). Pancreatic intraglandular metastasis predicts poorer outcome in post-operative patients with pancreatic ductal carcinoma. The American journal of surgical pathology, 37(7), 1030-1038.
39. Okabayashi, T., Shima, Y., Sumiyoshi, T., Sui, K., Iwata, J., Morita, S., … & Iiyama, T. (2018). A novel physiobiological parameter-based grading system for resectable pancreatic cancer. Annals of surgical oncology, 25(7), 1889-1895.
40. Xie, H., Lin, J., Thomas, D. G., Jiang, W., & Liu, X. (2012). Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma. International Journal of Clinical and Experimental Pathology, 5(4), 347.
41. Xu, J., Shi, K. Q., Chen, B. C., Huang, Z. P., Lu, F. Y., & Zhou, M. T. (2017). A nomogram based on pre-operative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma. Journal of Gastroenterology and Hepatology, 32(7), 1394-1402.
42. Yamada, M., Sugiura, T., Okamura, Y., Ito, T., Yamamoto, Y., Ashida, R., … & Uesaka, K. (2018). Microscopic venous invasion in pancreatic cancer. Annals of surgical oncology, 25(4), 1043-1051.
43. Yamaki, S., Yanagimoto, H., Tsuta, K., Ryota, H., & Kon, M. (2017). PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining. International journal of clinical oncology, 22(4), 726-733.
44. Zhang, Y., Frampton, A. E., Cohen, P., Kyriakides, C., Bong, J. J., Habib, N. A., … & Jiao, L. R. (2012). Tumor infiltration in the medial resection margin predicts survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery, 16(10), 1875-1882.
45. Rahib, L, Smith, BD, Aizenberg, R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913–2921.
46. Ferlay, J, Partensky, C, Bray, F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol 2016; 55: 1158–1160.
47. Maire, F, Cibot, J-O, Compagne, C, et al. Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database. Eur J Gastroenterol Hepatol 2017; 29: 904–908.
48. Pancreatic Cancer – Cancer Stat Facts. Available from: https://seer.cancer.gov/statfacts/html/pancreas.html.
49. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. 10.3322/caac.21492
50. Egawa S, Toma H, Ohigashi H, et al. Japan Pancreatic Cancer Registry;30th year anniversary: Japan Pancreas Society. Pancreas 2012;41:985-92. 10.1097/MPA.0b013e318258055c
51. Tseng JF, Tamm EP, Lee JE, et al. Venous resection in pancreatic cancer surgery. Best Pract Res Clin Gastroenterol 2006;20:349-64. 10.1016/j.bpg.2005.11.003
52. Nikfarjam M, Warshaw AL, Axelrod L, Deshpande V, Thayer SP, Ferrone CR, et al. Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg. 2008;247:165–172.
53. Kazanjian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumours: results of 70 cases. Arch Surg. 2006;141:765–769.
54. Winter J, Cameron J, Campbell K, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-Institution experience. J Gastrointest Surg. 2006; 10: 1199– 1211.
55. Katz MHG, Merchant NB, Brower S, et al. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 2010; 18: 337– 344.